YanXingMD

PubMed

• A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors.
  Maxime Chénard-Poirier, Aaron R Hansen, Martin E Gutierrez, Drew Rasco, Yan Xing, Lin-Chi Chen, Heng Zhou, Andrea L Webber, Tomoko Freshwater, Manish R Sharma> ;Investigational New Drugs. 2024 Mar 14
• The Combined Effect of Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors on Thyroid Function.
  Ma, H., Tsai, K., Xing, Y., Chung, S., Dorff, T., Bell, D., Lechner, M., Liang, T.> ;Thyroid. 2024 Feb 1
• 1 citations
  Integrating Early-Stage Drug Development with Clinical Networks; Challenges and Opportunities: The City of Hope Developing Experience.
  Miguel A Villalona-Calero, Jyoti Malhotra, Vincent Chung, Yan Xing, Stacy W Gray, Heather Hampel, Stephen Gruber, Kevin McDonnell> ;Journal of Clinical Medicine. 2023 Jun 15
• 7 citations
  Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors HarboringAmplification.
  Elias, A., Siqing Fu, Shuyang Yao, Yuan Yuan, Rebecca A Previs, Anthony D Elias, Richard D Carvajal, Thomas J George, Ying Yuan, Lihou Yu, Shannon N Westin, Yan Xing, ...> ;Journal of Clinical Oncology. 2023 Mar 20
• 6 citations
  Talimogene Laherparepvec (T-VEC): A Review of the Recent Advances in Cancer Therapy.
  Tiantian Zhang, Tony Hong-Ting Jou, Jerline Hsin, Zhe Wang, Kelly Huang, Jian Ye, Holly Yin, Yan Xing> ;Journal of Clinical Medicine. 2023 Jan 31
• Safety and efficacy of immune checkpoint inhibitor cancer therapy in patients with preexisting type 1 diabetes mellitus.
  Robin Hilder, Karen Tsai, Zoe Quandt, Dayna Isaacs, Alexandra Drakaki, Yan Xing, Gino K In, Trevor E Angell, Melissa G Lechner> ;Frontiers in Endocrinology. 2023 Jan 1
• A Phase I Dose-Escalation and Dose-Expansion Study of FCN-437c, a Novel CDK4/6 Inhibitor, in Patients with Advanced Solid Tumors.
  Amita Patnaik, Erika Hamilton, Yan Xing, Drew W Rasco, Lon Smith, Ya-Li Lee, Steven Fang, Jiao Wei, Ai-Min Hui> ;Cancers. 2022 Oct 12
• 3 citations
  The Role of Immunotherapy to Overcome Resistance in Viral-Associated Head and Neck Cancer
  Rebecca Pharaon, Yan Xing, Mark Agulnik, Victoria M. Villaflor> ;Frontiers in Oncology. 2021 Jul 16
• 1 citations
  Molecular and Clinical Features of Hospital Admissions in Patients with Thoracic Malignancies on Immune Checkpoint Inhibitors
  Dan Zhao, Haiqing Li, Isa Mambetsariev, Chen Chen, Rebecca Pharaon, Jeremy Fricke, Angel Ray Baroz, Prakash Kulkarni, Yan Xing, Erminia Massarelli, Marianna Koczywas, ...> ;Cancers. 2021 May 28
• 1 citations
  Narrative review of immunotherapy and radiation therapy in elderly patients
  Brittney Chau, Linda Ye, Yan Xing, Erminia Massarelli, Arya Amini, LaGuardia, J., Jonnby LaGuardia, Caressa Hui> ;Translational Cancer Research. 2021 May 1
• 7 citations
  Association of molecular characteristics with survival in advanced non-small cell lung cancer patients treated with checkpoint inhibitors.
  Dan Zhao, Isa Mambetsariev, Haiqing Li, Chen Chen, Jeremy Fricke, Patricia Fann, Prakash Kulkarni, Yan Xing, Peter P. Lee, Andrea Bild, Erminia Massarelli, Marianna Ko...> ;Lung Cancer. 2020 Aug 1
• 2 citations
  Untenable dosing: A common pitfall of modern DLT-targeting Phase I designs in oncology
  Paul Frankel, Vincent Chung, Yan Xing, Jeff Longmate, Susan Groshen, Edward M. Newman> ;Current Problems in Cancer. 2020 May 7
• 21 citations
  Prognosis of lymphotropic invasive micropapillary breast carcinoma analyzed by using data from the National Cancer Database.
  Gary D. Lewis, Yan Xing, Waqar Haque, Tejal Patel, Mary R. Schwartz, Albert C. Chen, Andrew M. Farach, Sandra S. Hatch, E. Brian Butler, Jenny C. Chang, Bin S. Teh> ;Cancer Communications. 2019 Oct 21
• 18 citations
  The impact of molecular status on survival outcomes for invasive micropapillary carcinoma of the breast.
  Gary D. Lewis, Yan Xing, Waqar Haque, Tejal Patel, Mary R. Schwartz, Albert C. Chen, Andrew M. Farach, Sandra S. Hatch, E. Brian Butler, Jenny C. Chang, Bin S. Teh> ;The Breast Journal. 2019 Jul 18
• 132 citations
  Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/ PTEN mutation
  Yan Xing, Nan Lin, Matthew A. Maurer, Huiqin Chen, Armeen Mahvash, Aysegul A. Sahin, Argun Akcakanat, Yisheng Li, Vandana G. Abramson, Jennifer K. Litton, Mariana Chav...> ;Breast Cancer Research. 2019 Jul 5
• 7 citations
  A Phase II Study of Capecitabine/Oxaliplatin With Concurrent Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Anal Canal.
  Cathy Eng, Alexandre A. Jácome, Prajnan Das, George J. Chang, Miguel A. Rodriguez-Bigas, John M. Skibber, Robert A. Wolff, Wei Qiao, Yan Xing, Salil Sethi, Aki Ohinata...> ;Clinical Colorectal Cancer. 2019 Jul 2
• 17 citations
  The impact of comorbidity on overall survival in elderly nasopharyngeal carcinoma patients: a National Cancer Data Base analysis.
  Ying Huang, Wei Chen, Waqar Haque, Vivek Verma, Yan Xing, Bin S. Teh, Edward Brian Butler> ;Cancer Medicine. 2018 Apr 1
• 52 citations
  Relation between the level of lymph node metastasis and survival in locally advanced head and neck squamous cell carcinoma.
  Yan Xing, Jianjun Zhang, Heather Lin, Kathryn A. Gold, Erich M. Sturgis, Adam S. Garden, J. Jack Lee, William N. William> ;Cancer. 2016 Feb 15
• 5 citations
  A Cost Analysis of Preoperative Breast MRI Use for Patients with Invasive Lobular Cancer
  Isabelle Bedrosian, Yan Xing, Shereen Abdel Rahman, Lisa R. Allen, Huong Le-Petross, Gary J. Whitman, Funda Meric-Bernstam, Kelly K. Hunt, Gildy Babiera, Janice N. Cor...> ;Annals of Surgical Oncology. 2016 Jan 1
• 111 citations
  Relationship Between Tumor Size and Survival in Non–Small-Cell Lung Cancer (NSCLC): An Analysis of the Surveillance, Epidemiology, and End Results (SEER) Registry
  Jianjun Zhang, Kathryn A. Gold, Heather Lin, Stephen G. Swisher, Yan Xing, J. Jack Lee, Edward S. Kim, William N. William> ;Journal of Thoracic Oncology. 2015 Apr 1
• 76 citations
  The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal
  Cathy Eng, George J. Chang, Y. Nancy You, Prajnan Das, Miguel A. Rodriguez-Bigas, Yan Xing, Jean Nicolas Vauthey, Jane E. Rogers, Aki Ohinata, Priyanka Pathak, Salil S...> ;Oncotarget. 2014 Oct 15
• 34 citations
  Is surveillance imaging effective for detecting surgically treatable recurrences in patients with melanoma? A comparative analysis of stage-specific surveillance strat...
  Natasha M. Rueth, Yan Xing, Yi Ju Chiang, Kate D. Cromwell, Merrick I. Ross, Jeffrey E. Lee, Jeffrey E. Gershenwald, Richard E. Royal, Janice N. Cormier> ;Annals of Surgery. 2014 Jun 1
• 128 citations
  Association Between Travel Distance and Metastatic Disease at Diagnosis Among Patients With Colon Cancer
  Nader N. Massarweh, Yi Ju Chiang, Yan Xing, George J. Chang, Alex B. Haynes, Y. Nancy You, Barry W. Feig, Janice N. Cormier> ;Journal of Clinical Oncology. 2014 Mar 20
• 79 citations
  Melanoma incidence rises for children and adolescents: an epidemiologic review of pediatric melanoma in the United States.
  Mary T. Austin, Yan Xing, Andrea Hayes-Jordan, Kevin P. Lally, Janice N. Cormier> ;Journal of Pediatric Surgery. 2013 Nov 1
• 19 citations
  Long-term results of weekly/daily cisplatin-based chemoradiation for locally advanced squamous cell carcinoma of the anal canal.
  Cathy Eng, George J. Chang, Y. Nancy You, Prajnan Das, Yan Xing, Marc E. Delclos, Robert A. Wolff, Miguel A. Rodriguez-Bigas, John M. Skibber, Aki Ohinata, Spencer Gou...> ;Cancer. 2013 Nov 1
• Join now to see all